INDRAPRASTHA MEDICAL share price has plunged 5% and is presently trading at Rs 424.1.
Meanwhile, the BSE HEALTHCARE index is at 43,994.1 (down 0.4%).
Among the top losers in the BSE HEALTHCARE index today are Sanofi India (down 2.9%) and DR. LAL PATHLABS (down 2.8%).
FORTIS HEALTHCARE (up 2.3%) and Abbott India (up 1.9%) are among the top gainers today.
Over the last one year, INDRAPRASTHA MEDICAL has moved up from Rs 169.1 to Rs 424.1, registering a gain of Rs 255.1 (up 150.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,800.9 to 43,994.1, registering a gain of 58.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 182.8%), SUVEN PHARMACEUTICALS (up 123.9%) and Glenmark Pharma (up 112.9%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 85,721.5 (up 0.6%).
The top gainers among the BSE Sensex today are Maruti Suzuki (up 4.7%) and M&M (up 3.3%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 26,189.9 (up 0.7%). Maruti Suzuki and M&M are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.7 to 85,721.5, registering a gain of 19,697.8 points (up 29.8%).
INDRAPRASTHA MEDICAL net profit grew 46.8% YoY to Rs 448 million for the quarter ended June 2024, compared to a profit of Rs 305 million a year ago. Net sales rose 13.5% to Rs 3,479 million during the period as against Rs 3,065 million in April-June 2023.
For the year ended March 2024, INDRAPRASTHA MEDICAL reported 43.9% increase in net profit to Rs 1,240 million compared to net profit of Rs 862 million during FY23. Revenue of the company grew 13.3% to Rs 12,447 million during FY24.
The current Price to earnings ratio of INDRAPRASTHA MEDICAL, based on rolling 12 month earnings, stands at 28.1.
Equitymaster requests your view! Post a comment on "INDRAPRASTHA MEDICAL Plunges 5%; BSE HEALTHCARE Index Down 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!